CryoPort (NASDAQ:CYRX) Research Coverage Started at Craig Hallum
by Sarita Garza · The Markets DailyCraig Hallum assumed coverage on shares of CryoPort (NASDAQ:CYRX – Free Report) in a report released on Monday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $15.00 price target on the stock.
Other equities research analysts also recently issued reports about the stock. Needham & Company LLC raised their target price on shares of CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a research report on Friday, March 27th. Finally, Wall Street Zen lowered CryoPort from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.94.
Check Out Our Latest Stock Analysis on CYRX
CryoPort Stock Performance
Shares of CryoPort stock opened at $8.51 on Monday. The company has a market capitalization of $424.31 million, a PE ratio of 6.45 and a beta of 1.68. The company has a 50-day simple moving average of $8.61 and a two-hundred day simple moving average of $9.27. CryoPort has a one year low of $4.63 and a one year high of $11.45.
CryoPort (NASDAQ:CYRX – Get Free Report) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The firm had revenue of $45.45 million during the quarter, compared to the consensus estimate of $42.92 million. CryoPort had a net margin of 42.35% and a negative return on equity of 8.22%. On average, equities analysts predict that CryoPort will post -0.99 earnings per share for the current fiscal year.
Insider Buying and Selling
In other CryoPort news, CEO Jerrell Shelton sold 7,918 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $8.00, for a total transaction of $63,344.00. Following the transaction, the chief executive officer owned 1,054,501 shares in the company, valued at approximately $8,436,008. This represents a 0.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Robert Stefanovich sold 38,700 shares of the firm’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $7.76, for a total transaction of $300,312.00. Following the completion of the transaction, the chief financial officer directly owned 255,701 shares of the company’s stock, valued at approximately $1,984,239.76. This represents a 13.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 59,939 shares of company stock worth $471,183 in the last three months. Corporate insiders own 10.00% of the company’s stock.
Institutional Investors Weigh In On CryoPort
Several institutional investors and hedge funds have recently made changes to their positions in CYRX. Basepoint Wealth LLC acquired a new position in shares of CryoPort in the 4th quarter valued at $34,000. Tower Research Capital LLC TRC lifted its position in CryoPort by 300.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after acquiring an additional 4,375 shares during the period. Whittier Trust Co. of Nevada Inc. purchased a new stake in CryoPort during the 3rd quarter valued at about $53,000. AlphaQuest LLC purchased a new stake in CryoPort during the 3rd quarter valued at about $79,000. Finally, PharVision Advisers LLC acquired a new position in shares of CryoPort in the second quarter valued at about $82,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.
About CryoPort
CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.
CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.